CD-10 Immunohistochemistry at Test Zone Diagnostic Center

CD-10 Immunohistochemistry at Test Zone Diagnostic Center

CD-10 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized, advanced histopathological analysis utilized to identify the expression of the CD10 antigen in tissue specimens. CD10, also historically known as the Common Acute Lymphoblastic Leukemia Antigen (CALLA), is a 100-kDa cell-surface zinc-dependent metalloendopeptidase. Under physiological conditions, this glycoprotein is expressed by various normal cell types, including precursor B-cells in the bone marrow, germinal center B-lymphocytes in lymphoid follicles, renal tubular epithelial cells, glomerular podocytes, breast myoepithelial cells, and endometrial stromal cells. However, its aberrant expression or loss of expression serves as an invaluable diagnostic marker in clinical oncology and pathology.

At Test Zone Diagnostic Center in Peshawar, Pakistan, this diagnostic test is performed using state-of-the-art automated immunohistochemical staining platforms. By applying highly specific monoclonal antibodies directed against the CD10 epitope, our consultant pathologists can visualize the precise localization of this antigen under a high-resolution light microscope. The primary clinical importance of CD-10 Immunohistochemistry lies in its exceptional diagnostic value for classifying hematolymphoid malignancies, subtyping renal epithelial neoplasms, and differentiating endometrial stromal tumors from smooth muscle lesions. This precise molecular characterization is essential for establishing an accurate diagnosis, determining prognosis, and formulating targeted therapeutic strategies for patients undergoing cancer evaluation.

Clinical Procedure: What to Expect

The clinical procedure for CD-10 Immunohistochemistry at Test Zone Diagnostic Center does not involve direct patient testing. Instead, the analysis is performed on tissue specimens previously obtained through surgical procedures, such as a needle biopsy, core biopsy, incisional biopsy, or complete surgical resection. Once the tissue is harvested, it undergoes a meticulous laboratory workflow to ensure the preservation of cellular morphology and antigenic sites.

The process begins with pre-analytical preparation, where the tissue specimen is fixed in 10% neutral buffered formalin to prevent autolysis. It is then processed and embedded in paraffin wax to create a Formalin-Fixed Paraffin-Embedded (FFPE) tissue block. Highly skilled histotechnicians cut ultra-thin sections (approximately 3 to 4 microns thick) using a precision microtome and mount them onto positively charged glass slides. These slides then undergo deparaffinization and rehydration through graded alcohols. To expose the CD10 antigen sites masked during formalin fixation, a heat-induced epitope retrieval (HIER) process is performed. The slides are then incubated with primary anti-CD10 monoclonal antibodies, followed by a polymer-based secondary detection system and a chromogen substrate (typically diaminobenzidine, which produces a visible brown precipitate). After counterstaining with hematoxylin to visualize cell nuclei, the slides are coverslipped and delivered to our expert consultant pathologists for detailed microscopic evaluation.

Patient Preparation

Because CD-10 Immunohistochemistry is performed on an excised tissue sample, there is no direct preparation required for the immunohistochemical staining process itself. However, patients must follow specific preparation guidelines for the primary biopsy or surgical procedure used to obtain the tissue specimen. These preparations vary depending on the anatomical site being sampled:

• Coagulation Profile: Patients undergoing invasive biopsies (such as a renal biopsy, liver biopsy, or deep lymph node biopsy) must undergo pre-procedure blood tests, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), and International Normalized Ratio (INR), to assess bleeding risks.
• Medication Adjustments: Under the guidance of the referring physician, patients may need to temporarily discontinue blood-thinning medications, such as aspirin, clopidogrel, warfarin, or low-molecular-weight heparin, several days prior to the biopsy.
• Fasting Requirements: If the biopsy or surgical resection requires local anesthesia with conscious sedation, regional anesthesia, or general anesthesia, patients are typically required to fast (nil by mouth) for 6 to 8 hours before the procedure.
• Post-Biopsy Care: Patients should arrange for a family member or friend to drive them home after the procedure, especially if sedatives are administered. Following the specific post-operative wound care instructions provided by the surgeon is vital to prevent infection.

During the Procedure

The laboratory phase of CD-10 Immunohistochemistry at Test Zone Diagnostic Center is executed under strict quality-controlled conditions to ensure diagnostic accuracy. The procedure involves several highly regulated steps:

• Specimen Verification: Upon arrival at our Peshawar laboratory, the tissue block or pre-cut slides are cross-referenced with the patient’s clinical requisition form to prevent any identification errors.
• Positive and Negative Controls: To verify the efficacy of the staining run, control tissues are processed alongside the patient’s sample. Normal tonsil tissue or renal cortex tissue is typically used as a positive control, while omitting the primary antibody on a control slide serves as the negative control.
• Automated Staining Run: The slides are loaded into our advanced automated IHC stainer, which precisely controls incubation times, temperatures, and reagent volumes, minimizing manual handling errors and background staining.
• Pathologist Analysis: The stained slide is examined under a light microscope by a consultant pathologist. The pathologist evaluates the intensity (weak, moderate, or strong) and pattern (membranous, cytoplasmic, or canalicular) of the brown chromogen staining within the target cells.
• Reporting: The pathologist correlates the CD10 staining pattern with the hematoxylin and eosin (H&E) morphological findings and other immunohistochemical markers to compile a comprehensive diagnostic report.

When is a CD-10 Immunohistochemistry Performed?

Evaluation and Classification of Acute Leukemias

CD-10 Immunohistochemistry is highly critical in the workup of acute leukemias. Because CD10 is also known as the Common Acute Lymphoblastic Leukemia Antigen (CALLA), its expression is a hallmark feature of precursor B-cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL). Pathologists utilize this marker on bone marrow trephine biopsies to differentiate B-ALL from T-cell Acute Lymphoblastic Leukemia (T-ALL) and Acute Myeloid Leukemia (AML), which are typically CD10-negative. Identifying the exact lineage of leukemia is essential for selecting the correct chemotherapy protocol.

Subtyping of Non-Hodgkin Lymphomas

In hematopathology, CD-10 is an indispensable marker for subtyping mature B-cell non-Hodgkin lymphomas. Normal germinal center B-cells express CD10; therefore, lymphomas arising from these cells, such as Follicular Lymphoma and Burkitt Lymphoma, typically show strong CD10 positivity. Conversely, other lymphomas like Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Small Lymphocytic Lymphoma are generally CD10-negative. This differentiation is vital, as the clinical course and treatment strategies for these lymphomas differ significantly.

Diagnosis of Renal Cell Carcinoma (RCC)

CD-10 Immunohistochemistry is widely used in the diagnostic evaluation of renal epithelial tumors. Clear Cell Renal Cell Carcinoma (ccRCC) and Papillary Renal Cell Carcinoma typically demonstrate strong, diffuse membranous and cytoplasmic CD10 expression. In contrast, Chromophobe Renal Cell Carcinoma and Oncocytoma are usually negative or show only focal, weak staining. This marker is particularly useful when analyzing metastatic lesions of unknown primary origin, helping confirm a renal source.

Identification of Endometrial Stromal Tumors

In gynecologic pathology, distinguishing endometrial stromal tumors from smooth muscle tumors can be highly challenging due to overlapping morphological features on standard H&E stains. CD-10 is highly expressed in normal endometrial stroma and endometrial stromal sarcomas (ESS). Conversely, uterine leiomyomas and leiomyosarcomas generally show absent or only focal CD10 expression. Utilizing CD-10 IHC helps pathologists confidently diagnose aggressive stromal malignancies.

Characterization of Undifferentiated and Metastatic Neoplasms

When patients present with metastatic tumors of unknown primary origin, pathologists employ a panel of immunohistochemical stains, including CD-10, to narrow down the differential diagnosis. CD10 positivity, when combined with other markers like Cytokeratins, PAX8, and TTF-1, helps identify or rule out primary sites such as the kidneys, bladder (urothelial carcinoma), liver (hepatocellular carcinoma showing a canalicular pattern), or skin (basal cell carcinoma).

What Does a CD-10 Immunohistochemistry Detect?

CD-10 Immunohistochemistry detects the presence, distribution, and intensity of the CD10 metalloendopeptidase enzyme within a tissue sample. Specifically, it can detect:

• Strong membranous positivity in lymphoblasts, confirming a diagnosis of precursor B-cell Acute Lymphoblastic Leukemia.
• Diffuse germinal center-like positivity in nodal biopsies, supporting a diagnosis of Follicular Lymphoma.
• Strong membranous and cytoplasmic expression in renal cortical biopsies, indicating Clear Cell Renal Cell Carcinoma.
• Diffuse cytoplasmic staining in uterine biopsies, confirming Endometrial Stromal Sarcoma.
• Canalicular staining patterns in liver biopsies, which is highly characteristic of Hepatocellular Carcinoma.
• Strong, diffuse positivity in Burkitt Lymphoma cells, aiding in its differentiation from other high-grade B-cell lymphomas.
• Positive staining in the neoplastic T-cells of Angioimmunoblastic T-cell Lymphoma (AITL).
• Presence of CD10 in myoepithelial cells of the breast, helping confirm an intact myoepithelial layer in ductal carcinoma in situ (DCIS) and distinguishing it from invasive ductal carcinoma.
• Strong positivity in cutaneous Basal Cell Carcinoma, helping differentiate it from other cutaneous adnexal tumors.
• Positive staining in atypical fibroxanthoma of the skin.
• Absence of staining in Mantle Cell Lymphoma, helping rule out this specific subtype.
• Negative staining in Marginal Zone Lymphoma.
• Negative or weak focal staining in Chromophobe Renal Cell Carcinoma.
• Negative staining in uterine Leiomyosarcoma, helping differentiate it from endometrial stromal tumors.
• Normal CD10 expression in mature neutrophilic granulocytes, serving as an internal positive control.
• Normal CD10 expression in renal glomerular podocytes and proximal tubule brush borders.
• Normal CD10 expression in the germinal centers of reactive lymph nodes.
• Altered or lost CD10 expression in specific high-grade urothelial carcinomas.
• Positive staining in the stromal cells of giant cell tumors of bone.
• Positivity in pancreatic solid pseudopapillary neoplasms.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Peshawar, we understand that waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry involves complex, multi-step laboratory processing—including tissue fixation, embedding, microtomy, antigen retrieval, antibody incubation, and expert microscopic review by a consultant pathologist—the turnaround time for CD-10 Immunohistochemistry is typically 3 to 5 working days from the receipt of the specimen.

Once the diagnostic report is finalized and signed off by our consultant pathologist, patients receive an automated SMS notification on their registered mobile number. Reports can be accessed instantly and downloaded in PDF format via the secure online portal on the Test Zone Diagnostic Center official website. Physical copies of the report can also be collected directly from our main diagnostic facility in Peshawar or designated collection centers.

CD-10 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Lymph Node Germinal Centers	Strong positive staining restricted to germinal center B-cells.	Diffuse positive staining outside normal follicular boundaries, indicating Follicular Lymphoma.
Bone Marrow Lymphoblasts	Negative or rare positive precursor cells (hematogones).	Diffuse, strong membranous positivity indicating B-cell Acute Lymphoblastic Leukemia (B-ALL).
Renal Epithelial Tissue	Positive staining in glomerular podocytes and proximal tubular brush borders.	Strong, diffuse membranous and cytoplasmic staining in Clear Cell Renal Cell Carcinoma.
Uterine Stroma / Myometrium	Positive staining in normal endometrial stroma (proliferative phase).	Diffuse, intense positive staining in Endometrial Stromal Sarcoma; negative in Leiomyosarcoma.
Breast Tissue	Continuous positive staining in the outer myoepithelial cell layer of ducts.	Disruption or complete loss of CD10-positive myoepithelial layer, indicating invasive breast carcinoma.
Liver Tissue	Distinct canalicular staining pattern in normal hepatocytes.	Altered or diffuse cytoplasmic staining in Hepatocellular Carcinoma.
Skin Biopsy	Negative in normal epidermal keratinocytes.	Strong positive expression in Basal Cell Carcinoma or Atypical Fibroxanthoma.
Peripheral Blood / Bone Marrow Granulocytes	Positive staining in mature, healthy neutrophils.	Decreased or abnormal staining patterns in certain myelodysplastic syndromes (MDS).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-10 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in histopathology and immunohistochemical interpretation.
• Advanced Diagnostic Technology: We utilize state-of-the-art automated immunohistochemistry staining platforms to ensure highly reproducible, standardized, and accurate results.
• Comprehensive Antibody Menu: Test Zone Diagnostic Center offers a wide range of primary antibodies, allowing for comprehensive diagnostic panels to resolve complex oncological cases.
• Stringent Quality Control: We implement rigorous internal and external quality control protocols for every staining run to ensure the highest diagnostic reliability.
• Patient-Focused Care: We prioritize patient comfort and convenience, providing clear instructions and compassionate support throughout the diagnostic journey.
• Convenient Location: Our main diagnostic facility is centrally located in Peshawar, making it easily accessible for patients across the region.
• Secure Online Portal: Patients can easily view, download, and share their diagnostic reports through our secure, user-friendly online portal.
• Professional Reporting: We provide detailed, clinically actionable pathology reports that assist referring oncologists and surgeons in planning optimal treatment pathways.